IOVA241220P9000
- 1.31
- +0.31+31.00%
Iovance Biotherapeutics Newsroom
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
JMP Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $23
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $21 to $32
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $25
Iovance Biotherapeutics Analyst Ratings
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
Promising Efficacy and Long-term Response of Iovance Biotherapeutics' Lifileucel in NSCLC: A Buy Recommendation
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Analyst Ratings
UBS Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $17
Piper Sandler Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating, Maintains Target Price $10
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $23
Stifel Nicolaus Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Baird Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $24
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating